Boston and Stockholm-based Aprea Therapeutics, a clinical-stage biotechnology company developing novel anticancer therapies targeting the p53 tumor suppressor protein, has priced its IPO of 5 million shares between $14 and $16 per share. Aprea is backed by Redmile Group, Rock Springs Capital, 5AM Ventures, Versant Ventures, HealthCap, Sectoral Asset Management and Karolinska Development AB.
STOCKHOLM – September 23, 2019, Karolinska Development AB (Nasdaq Stockholm: KDEV) announces that its portfolio company Aprea Therapeutics (Aprea) today has filed an amendment to the registration statement filed on September 6, 2019 with the U.S. Securities and Exchange Commission (SEC) and has set the price range for the potential initial public offering of its shares of common stock at USD 14-16 per share.
Provided the completion of the initial public offering, the net profit effect due to changed valuation of the Karolinska Development AB holding, based on the price range in the offering, would be approx. SEK 45-78 million. Karolinska Development has signed a customary lock up agreement, preventing a sale of the shares during a 180 days period calculated from the end of the offer period.
A registration statement relating to these securities, including the amendment, has been filed with the SEC but has not yet become effective. These securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.